Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss
Y Gao, J Shen, E Choy, H Mankin, F Hornicek, Z Duan - Cellular oncology, 2017 - Springer
Y Gao, J Shen, E Choy, H Mankin, F Hornicek, Z Duan
Cellular oncology, 2017•SpringerPurpose Overexpression of cyclin-dependent kinase (CDK) 4 has been observed in a
variety of cancers and has been found to contribute to tumor cell growth and proliferation.
However, the effect of inhibition of CDK4 in ovarian cancer is unknown. We investigated the
therapeutic effect of the CDK4 inhibitor palbociclib in combination with paclitaxel in ovarian
cancer cells. Methods Cell viabilities were determined by MTT assay after exposure to
different dosages of palbociclib and/or paclitaxel. Western blot, immunofluorescence, and …
variety of cancers and has been found to contribute to tumor cell growth and proliferation.
However, the effect of inhibition of CDK4 in ovarian cancer is unknown. We investigated the
therapeutic effect of the CDK4 inhibitor palbociclib in combination with paclitaxel in ovarian
cancer cells. Methods Cell viabilities were determined by MTT assay after exposure to
different dosages of palbociclib and/or paclitaxel. Western blot, immunofluorescence, and …
Purpose
Overexpression of cyclin-dependent kinase (CDK) 4 has been observed in a variety of cancers and has been found to contribute to tumor cell growth and proliferation. However, the effect of inhibition of CDK4 in ovarian cancer is unknown. We investigated the therapeutic effect of the CDK4 inhibitor palbociclib in combination with paclitaxel in ovarian cancer cells.
Methods
Cell viabilities were determined by MTT assay after exposure to different dosages of palbociclib and/or paclitaxel. Western blot, immunofluorescence, and Calcein AM assays were conducted to determine the mechanisms underlying the cytotoxic effects of palbociclib in combination with paclitaxel. CDK4 siRNA was used to validate the outcome of targeting CDK4 by palbociclib in ovarian cancer cells.
Results
We found that combinations of palbociclib and paclitaxel significantly enhanced drug sensitivity in both Rb-positive (SKOV3TR) and Rb-negative (OVCAR8TR) ovarian cancer-derived cells. When combined with paclitaxel, palbociclib induced apoptosis in both SKOV3TR and OVCAR8TR cells. We also found that palbociclib inhibited the activity of P-glycoprotein (Pgp), and that siRNA-mediated CDK4 knockdown sensitized multidrug resistant (MDR) SKOV3TR and OVCAR8TR cells to paclitaxel.
Conclusions
Inhibition of CDK4 by palbociclib can enhance paclitaxel sensitivity in both Rb-positive and Rb-negative MDR ovarian cancer cells by increasing apoptosis. CDK4 may serve as a promising target in the treatment of ovarian cancer.
Springer